Howard Kaufman, MD, on Merkel Cell Carcinoma: Treatment Update

2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Tweet this page

Howard Kaufman, MD, of Rutgers Cancer Institute of New Jersey, discusses a subgroup analysis of efficacy results on avelumab in chemotherapy-refractory metastatic Merkel cell carcinoma. (Abstract 80)

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.